GlaxoSmithKline liberalizes release of clinical trial data
October 11th, 2012 by Staff
GlaxoSmithKline (GSK), the manufacturer of pazopanib (Votrient), announced Thursday, October 11th that they make detailed data from their clinical trials available to researchers. These data presumably were not all available before, either to drug approval agencies (the Food and Drug Administration and the European Medicines Agency) or to external researchers. This release applies to drugs that have already been approved or ones for whose research has been discontinued.
The objective on the part of GSK is to be more transparent. GSK was fined $3 billion this summer by the US Justice Department due to its withholding of information about increased risk for heart failure and heart attack during use of its anti-diabetes drug Avandia.
People are hopeful that the release of full clinical data could lead external researchers to develop more effective drugs, or, at least, provide a full side-effect profile that was not heretofore available for current drugs. If this new policy were to be followed by other drug companies, this would help oncologists make better choices about which drugs of similar efficacy to prescribe to cancer patients based on the side effects of the drug and the health issues of individual patients.
Note that GSK, in a previous effort at transparency, started reporting on their current trial protocols and summaries of results, including renal cell carcinoma, on their website at http://www.gsk-clinicalstudyregister.com/.